New data on MIV-818 will be presented at EASL's International Liver Congress™ 2017

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR ) today informs that preclinical data on MIV-818 will be presented by Medivir at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April. The poster presentation, abstract SAT-123, is entitled “Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers” and will include data on the anticancer activity and pharmacokinetic profile of MIV-818.

Details of all presentations for The International Liver Congress™ 2017 are available at the website: http://www.easl.eu/ .

    
For further information, please contact:

Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211

Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

About Medivir
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

Tags:

About Us

Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals.Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links